Thrust Areas of Research
Our R&D approach towards uncluttered spaces and unique therapies has pushed us to develop novel solutions that fill the gap between challenging ailments and available molecules. With the objective of saving human life through innovations, we are focusing on:
|Development of Novel Antibiotic Adjuvant Entity (AAE) to combat growing anti-microbial resistance
AAE is a technology developed to potentiate the already existing antibiotics by adding on antibiotics adjuvant and enabling the existing antibiotics to be effective even in various multi-drug resistant infections. VMRC has been using this technology in its various novel antibiotics which are effective against even the toughest carbapenemase resistant Metallobetalactamses, Quinolones and aminoglycoside set of antibiotics resistance and shows outstanding results as it not only kills resistant pathogens but also prevents the spread of resistance.
|Novel Drug Delivery System (NDDS)
VMRC has achieved success in developing nanotechnology based sustained release and target delivery formulation with NDDS. This has helped the company to develop formulations with reduced side-effects in various therapeutic areas such as Oncology,NSAIDs, Neuroscience, Arthritic disorders, Stress, Lifestyle related diseases, infectious diseases and wound healing. NDDS improves drug potency,control drug release to give a sustained therapeutic effect and provide greater safety. It is used to target a drug specifically to a desired tissue.
|Target based Oncology Drug Delivery
VMRC is working on target based drug delivery for cancer treatment. The company has designed a platform technology with a novel concept of triple conjugate i.e. Drug Protein Polymer Conjugate (DPPC). Triple conjugate employs a protein moiety capable of binding selectively to a particular target site (affected organ), a polymer moiety covalently linked to a protein, and an active drug moiety. Based on specificity of the target organ, various components of DPPC can be rationally selected.
|Developing Diagnostic device for early detection
Understanding the need to detect and diagnose a life threatening problem at an early stage will help the mankind to have an improved and better life. Working on these lines, VMRC has come up with two such techniques. One is for Typhoid that will help diagnose the disease within a few minutes as compared the traditional 48 hours detection time. Other technique is using VRP1620 which will facilitate cancer detection through simple X-trays in a few hours as opposed to the conventional 12-15 days.